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http:WHAT THIS PAPER ADDS?
In a growing subset of patients with exhausted upper extremity veins and repeated prosthetic graft failures, the
arm composite autogenous vascular access (ACAVA), using the great saphenous vein and the femoral vein
transposed to the arm, has been thought to be an autologous alternative. This study reports our results with
ACAVA and evaluates its role in patients with complex needs regarding haemodialysis access.
Despite the high rate of postoperative complication and the need for re-intervention, ACAVA is a useful
alternative for patients with poor vascular access options.Objectives: The objective is to report our results with the arm composite autogenous vascular access (ACAVA)
using the great saphenous vein (GSV) and the femoral vein (FV) in tertiary vascular access surgery.
Design: Retrospective single-centre study. Prospectively collected clinical database.
Methods: Between August 2009 and March 2011, 17 patients with no suitable upper extremity vein, repeated
prosthetic access failure and/or infection underwent the construction of an ACAVA. Outcome measures included
the graft patency and complication rates.
Results: The median follow-up was 25 months (5e32). Thirty-day morbidity affected 10 patients (59%): four
wound-healing issues, three lower limb swelling, two early thromboses and one upper limb haematoma. No
postoperative death occurred. At 3 months, the primary patency rate was 88%  8%. At 6 months, the assisted-
primary patency rate was 82.4%  9.2%. At 12 months, the secondary patency rate was 81.6%  9.6%. Twenty-
four secondary interventions were performed. Steal syndrome occurred in one patient following a secondary
procedure. Swelling of the lower limb remained in two patients at the end of their follow-up. Three ACAVAs
developed irreversible occlusion leading to loss of access.
Conclusion: With a high rate of postoperative morbidity and re-intervention, the ACAVA is a useful additional
technique that should be restricted to difﬁcult cases with limited vascular access options.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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constantly increasing, and maintaining their vascular access
has become a challenging problem.1,2 Both the American
National Kidney Foundation guidelines for vascular access
(Kidney Disease Outcomes and Quality Initiative) (NFK/
KDOQI)3 and the European Best Practice guidelines4 have
recently re-emphasised the beneﬁts of autogenoussented at the European Society for Vascular Surgery (ESVS) 2012
Meeting in Bologna, Italy.
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//dx.doi.org/10.1016/j.ejvs.2012.11.030conﬁgurations. In a growing subset of patients with
exhausted upper extremity veins, repeated prosthetic graft
failure and/or infection, the femoral vein (FV) transposed to
the upper limb has been described as an efﬁcient autolo-
gous graft in terms of patency, due to its large diameter (6e
10 mm) and the short time needed for maturation.5e9
However, the large amount of blood ﬂowing through the
graft is eventually responsible for increased ischaemic
complications (steal syndrome).6
Arm composite autogenous vascular access (ACAVA),
using the great saphenous vein (GSV) and the FV transposed
to the arm, has been thought of as an alternative to limit
the blood ﬂow and avoid ischaemic complications, without
being evaluated.5 This study reports our results with ACAVA
and evaluates its role in the creation of vascular access for
patients with complex needs regarding haemodialysis
access.
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The clinical data of patients who underwent the construc-
tion of an ACAVA in our department of vascular surgery
between August 2009 and March 2011 were prospectively
collected in a computerised database and retrospectively
analysed. Demographic data, cardiovascular risk factors and
the cause of end-stage renal disease (ESRD) were noted for
each patient. The number, locations and type of any
previous vascular access were recorded, as were all tech-
nical details of the ACAVA construction, including the
duration of the procedure.
The study was conducted according to the Declaration of
Helsinki, and our institutional ethic committee approved
this protocol. Patients gave informed consent before being
included in the study.
As a teaching hospital, our institution collaborates with
surrounding hospitals and private dialysis centres to
manage their complicated cases of vascular access. All these
patients had no suitable upper extremity vein identiﬁed by
duplex scan, repeated prosthetic access failures and/or
infections. Duplex scanning of both upper and lower limb
vessels was performed preoperatively to rule out any
occlusive lesion and assess diameters.
All ACAVAs were constructed by an experienced vascular
surgeon from our department. All patients were operated
under general anaesthesia in dorsal decubitus with one
upper and one lower extremity abducted on the operated
side.
Fig. 1 presents the usual conﬁguration of ACAVA per-
formed in our department.
The operative technique began with exposure of the
brachial artery proximal to the antecubital fossa, and the
axillary vein 2 cm below the clavicle. A bolus of 3500eFigure 1. Conﬁguration of the ACAVA, after harvesting both FV and GSV
GSV: great saphenous vein.5000 IU of unfractionated heparin was administered based
on the patient’s weight. A 25e30 cm segment of the FV was
harvested before the profunda femoris vein joined up to it,
through an incision that extended from the traditional
incisions of the common femoral and above-knee popliteal
vessels. After harvesting a 5 cm segment of GSV in the
groin, end-to-end anastomosis was performed between the
two segments with interrupted non-absorbable suture. The
composite graft was then interposed through a tunnel
between the two incisions of the upper arm, in the reverse
position. End-to-side anastomoses were performed
between the FV and the axillary vein, and ﬁnally between
the GSV and the brachial artery.
After unclamping, the presence of a thrill in the ACAVA
was systematically veriﬁed. Aspiration drainage was placed
in the thigh and the subclavian incisions before closure.
Postoperatively, a low dose of heparin was administered
for 15 days in order to prevent deep-vein thrombosis.
Elastic stockings were worn on the operated lower limb for
at least 3 months and were kept on for as long as necessary
in cases of recurrent swelling.
The ACAVA could be used for haemodialysis 3 weeks
after the procedure. This waiting period was chosen in order
to avoid bleeding and haematoma complications.
During follow-up, the ACAVA was monitored by both
nephrologists and vascular surgeons.
The nephrologists monitored the blood ﬂow in the graft
by duplex scan and the compression time required for
haemostasis after haemodialysis. Clinical examination was
performed by the surgeon 1, 3, and 6 months after hospital
discharge, or at any time on the nephrologist’s demand. All
complications were noted with their date of onset. In the
case of permanent thrombosis, the cause and the alterna-
tive vascular access used were also recorded.from the thigh. A: axillary vein; B: brachial artery; FV: femoral vein;
Table 1. Population characteristics.
Number of patients 17
Male 5 29%
Female 12 71%
Risk factors
Hypertension 14 82%
Diabetes 7 41%
Current smoking (<3 years) 3 18%
Hyperlipidaemia 8 47%
Comorbid diseases
Coronary artery disease 4 24%
Peripheral arterial disease 6 35%
ASA classiﬁcation
ASA 2 3 18%
ASA 3 14 82%
Aetiology of ESRD
Diabetic nephropathy 5 29%
Nephroangiosclerosis 5 29%
Renal polycystosis 2 12%
Toxic nephropathy 1 6%
Chronic interstitial nephropathy 1 6%
Undetermined 3 18%
ASA: American Society of Anesthesiologists; ESRD: end-stage renal
disease.
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patency. The secondary outcomes were the primary and
assisted-primary patency and the complication rate after
ACAVA creation.
In agreement with the recommended standards, all re-
ported patency rates were functional patency rates. An
access was deﬁned as functional when able to deliver a ﬂow
rate of 350e400 ml min1 without access recirculation to
maintain a treatment time of less than 4 h.
The primary patency was deﬁned as the interval from the
time of access placement until any intervention designed to
maintain or re-establish patency, or to access thrombosis or
the time of measurement of patency. The assisted-primary
patency was deﬁned as the interval from the time of access
placement until access thrombosis or the time of
measurement of patency, including any intervention
designed to maintain the functionality of a patent access.
The secondary patency was deﬁned as the interval from the
time of access placement until access abandonment,
thrombosis, or the time of patency measurement including
interventions designed to maintain or re-establish func-
tionality in a thrombosed access.
The severity of the complications was graded from 0 to 3
in accordance with the reporting standards.10
Statistical analysis was performed with StatView software
(SAS Institute, Inc., Cary, NC, USA; version 5.0).
All results were calculated on an intention-to-treat-basis.
Nominal variables were expressed as a number and
a percentage of patients. Continuous variables were
expressed as the mean standard deviation or the range for
non-Gaussian distributions. The Kaplan Meier life-table
method was used to calculate patency curves. A value of
P < 0.05 was considered to indicate statistical signiﬁcance.RESULTS
Between August 2009 and March 2011, among the 196
haemodialysis vascular accesses created in our department,
17 patients (5 men, 12 women) with a mean age of 70 years
(range 38e88 years) underwent an ACAVA construction.
Patient demographic data, risk factors for arteriosclerosis,
co-morbidities and main causes of ESRD are summarised in
the Table 1.
These 17 patients had been on chronic haemodialysis for
a mean of 27 months (range 0e122).
ACAVAwas constructed as the ﬁrst access procedure in one
patient with no suitable upper extremity vein and relative
contraindication to prosthetic material due to chronic infec-
tion. This patient had not started haemodialysis before the
ACAVA creation. Among the 16 other patients whose venous
access sites were exhausted due to repeated failed autoge-
nous (n ¼ 42) and prosthetic vascular accesses (n ¼ 27), six
had a chronic prosthetic graft infection. The mean number of
previous accesses per patient was 4 (range 0e7).
The ACAVAs were constructed on the right side in ﬁve
patients and on the left side in 12 patients. The mean
operating time was 275  52 min. The mean duration of the
hospitalisation was 5  2 days.Thirty-day morbidity affected 10 patients (59%): four
wound issues (noninfectious ﬂuid collections observed in
the thigh, resulting in a delay in healing but resolved
without surgical drainage, severity 1), three swellings of the
lower limb (severity 1), two vascular access early throm-
boses (needed revision with clot removal, severity 2), and
one upper limb bleeding (resolved without treatment,
severity 1). No postoperative death occurred, but two
patients (12%) died 5 and 17 months after the procedure,
from mesenteric infarction and end-stage cancer of the
cervix, respectively.
The mean ﬁrst time to access was 31 days (range 22e48)
and the mean time to dialysis initiation was 35 days (range
24e53).
The median follow-up was 25 months (range 5e32
months). At 3 months, the primary patency rate was
88%  8%. At 6 months, the assisted-primary patency rate
was 82.4%  9.2%. At 12 months, the secondary patency
rate was 81.6%  9.6%. Patency rates after these time
points are to be taken with caution because of SE >10%
(Fig. 2).
A total of 24 secondary interventions were performed on
14 patients (between one and four procedures per patient).
Twelve were isolated percutaneous angioplasties, of which
seven concerned the arterial anastomosis or the GSV
segment and ﬁve concerned the venous anastomosis (two
required the use of a cutting balloon and one needed
a stent placement in the subclavian vein, above the ACAVA).
Nine were thrombectomies of the ACAVA, of which one
failed (neointimal hyperplasia of the FV), ﬁve were associ-
ated with the angioplasty of the arterial anastomosis or the
GSV segment and three needed a replacement of the GSV
segment. Two procedures for restenosis of the GSV segment
were performed with venous patch enlargements. One
Distal Revascularization Interval Ligation (DRIL) procedure
Figure 2. ACAVA: Kaplan Meier analysis of patency rates.
186 European Journal of Vascular and Endovascular Surgery Volume 45 Issue 2 February/2013was performed for steal syndrome that occurred in one
patient (6%) after a secondary procedure (percutaneous
angioplasty of the arterial anastomosis with an oversized
balloon).
Three ACAVAs (18%) developed irreversible occlusion
leading to loss of access (at 4, 6 and 9 months), including
one neointimal hyperplasia of the FV. Peritoneal dialysis
was initiated for two of those three patients; the last one
underwent placement of an indwelling Canaud catheter.
Swelling of the lower limb (severity 2) remained in two
ACAVA patients at the end of their follow-up.
Three patients (18%) had good results without any re-
intervention.
DISCUSSION
Numerous studies have described the FV as a useful
replacement conduit for vascular reconstructions.11e13 In
2000, Huber et al. ﬁrst described the use of FV as a conduit for
permanent haemodialysis access: transposed superﬁcially in
the thigh for one case and transposed to the arm in another
case.5 He advocated a diameter range from 6 to 10 mm and
a thick wall, comparing the FV to a mature arteriovenous
ﬁstula. In this original technical description, he used
a composite conﬁguration with both the FV and a small
segment of the GSV, for two reasons: to limit the blood ﬂow
through the graft and increase the overall length of the
access.5 This original conﬁguration was not further assessed,
as in a later experimentwith 30 FV accesses transposed to the
arm, he rarely used the GSV. Despite excellent patency rates,
he encountered 43% of hand ischaemia resulting in 27%
complementary DRIL procedures.6
These results led us to evaluate the role of the composite
conﬁguration in blood ﬂow limitation, through the ACAVA
technique. In our series, the original technique as described
by Huber et al.5 was slightly modiﬁed with a venous axillary
anastomosis made more proximally, at the end of the axil-
lary vein. This makes a long and straight venous line on the
upper arm available for easy cannulation (Fig. 1).Our secondary patency rate was similar to the ﬁgures
obtained with prosthetic AV grafts, which is acceptable for
patients in whom haemodialysis access is difﬁcult.14
However, our low primary patency rates show that
ACAVA needs close follow-up and re-interventions. We
noticed that in our series, neointimal hyperplasia of the GSV
segment was the main cause leading to thrombosis (8 out
of 9) whereas the FV developed hyperplasia in only one
case. Out of 24 re-interventions, 17 concerned the GSV
segment. On the other hand, the axillary venous anasto-
mosis required only ﬁve angioplasty procedures. This trend
towards thrombosis could be subsequent to the patient’s
predisposition to thrombophlebitis and intimal hyperplasia.
The use of GSV alone as an alternative haemodialysis
conduit has been previously reported but the authors
encountered the same complications (neointimal hyper-
plasia) with poor 1-year secondary patency rates (50%).15e
17 Our unpublished experience has led us to the same
results. In the ACAVA, close follow-up and re-intervention
may enable early treatment of stenosis of the GSV segment
and keep the cannulation site (FV segment) available for
use.
Contrary to the FV series,6 we encountered only one
hand ischaemia in our cohort, after a secondary procedure
of angioplasty using an oversized 7-mm balloon and
resulting in a complementary DRIL procedure.
The small diameter of the GSV seems to be of paramount
importance in preventing ischaemic complication. In their
FV transposition in the thigh, Gradman et al. described
another technique to limit the blood ﬂow: tapering the FV
to 4e5 mm by sutures, at the arterial anastomosis.18 With
this technique, the axillary anastomosis can be made at the
axilla to shorten the graft. It has not been described with
autogenous FV in the upper limb and should be assessed as
an alternative to the GSV interposition.
Our enthusiasm concerning ACAVA is also counter-
balanced by a high rate of postoperative morbidity (59%),
similar to that reported by Huber et al. (57%), apart from
N. Sadaghianloo et al. 187the ischaemic complications. Harvesting a deep vein in the
thigh is by no means trivial and requires a fair amount of
time, even though in our more recent experience, with two
surgeons cooperating, the operating time was reduced to
two and a half hours. We did not have any cases of post-
operative mortality, but four wound-healing issues (24%,
severity grade 1), which convalesced with conservative
management. We had three patients with limb swelling
(severity grade 2) within the postoperative time (18%), two
of whom were still wearing elastic stockings at the end of
their follow-up. However, Wells et al. studied the harvest of
86 FV and reported that the presence of collateral venous
channels between the popliteal vein stump and the pro-
funda femoris vein was one mechanism to preserve the
clinical status from venous complication. Furthermore, the
absence of the GSV did not adversely affect the clinical
outcome.19 This was consistent with our choice to make
a composite graft rather than harvesting an extending
segment of the femoro-popliteal vein.
Admittedly, all patients in our series could have received
either a recurrent prosthetic graft in the upper limb, an
axillary loop20 or a lower-limb arteriovenous access.
Considering the high frequency of access punctures for
haemodialysis, prosthetic grafts place these haemodialysis
patients at an increased risk of infectious and septic
complications.21,22 We subjectively determined that after
several infectious complications of prosthetic grafts and
relative contra-indication to any form of exogenous
material, the autogenous policy seemed a better alterna-
tive in our selected patients. In our series, we did not
encounter infectious complications in the upper limb. In
a systematic review, Antoniou et al. reported 18% of
severe infectious complication with prosthetic grafts of the
lower extremity, and 21% of distal limb ischaemia
secondary to steal syndrome with autogenous FV
transposition.23
We acknowledge some limitations in our present study.
This was a single-centre, non-randomised, non-controlled
study, involving a small number of patients (n ¼ 17). As
standard errors after 12 months went above 10% for the
secondary patency rate, our results should be considered
preliminary. The choice of any kind of arteriovenous
access must be clearly discussed with the treating
nephrologist according to the patient’s clinical history and
status.CONCLUSION
The ACAVA is a useful additional technique in the arma-
mentarium for tertiary access surgery. The composite
conﬁguration does limit ischaemic complications. However,
with a high rate of postoperative morbidity and re-inter-
vention, this technique should be restricted to difﬁcult cases
with limited vascular access options.
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